Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.56 |
| ▸ | MMP1 | P03956 | 4/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.55 |
| ▸ | MMP3 | P08254 | 4/20 | 0.55 |
| ▸ | MMP7 | P09237 | 4/20 | 0.55 |
| ▸ | MMP9 | P14780 | 4/20 | 0.55 |
| ▸ | MMP13 | P45452 | 4/20 | 0.55 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27475768 | 1.00 | CAPN1 (0.56) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL3840645 | 1.00 | CAPN1 (0.56) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL3913553 | 0.82 | CAPN1 (0.66) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL27615593 | 0.82 | CAPN1 (0.56) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL3904669 | 0.82 | CAPN1 (0.66) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL1907361 | 0.82 | CAPN1 (0.66) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL6026500 | 0.82 | CAPN1 (0.66) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL7769978 | 0.82 | ALOX5AP (0.44) | CAPN1 | |
| SCHEMBL5363846 | 0.82 | CAPN1 (0.66) | CAPN1MMP1MMP2MMP3MMP7 | |
| SCHEMBL27486757 | 0.82 | ADAM17 (0.55) | CAPN1MMP1MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927716-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |